Product Details
Xolair 150 mg/ml Injection (Omalizumab) In Pakistan
Xolair 150mg/ml Injection contains omalizumab, a recombinant monoclonal antibody that targets immunoglobulin E (IgE). By binding to IgE, omalizumab helps reduce IgE-mediated allergic inflammation and is used as part of specialist treatment for certain allergic and inflammatory conditions.
Xolair is available as a 150mg/ml prefilled syringe or autoinjector for subcutaneous administration. Depending on the patient's condition, age, body weight and clinical factors, the prescribed dose may require one or more injections at intervals determined by the treating physician.
Benefits
- Contains omalizumab 150mg/ml.
- Targets IgE-mediated allergic pathways.
- Used for selected patients with allergic asthma and other approved conditions.
- May help reduce symptoms and improve disease control when appropriately prescribed.
- Available in a convenient prefilled injection presentation.
- Administered subcutaneously.
- Suitable for individualized treatment under specialist medical supervision.
Specifications
| Specification | Details |
|---|---|
| Brand | Xolair |
| Active Ingredient | Omalizumab |
| Strength | 150mg/ml |
| Dosage Form | Injection |
| Route | Subcutaneous |
| Presentation | Prefilled Syringe / Autoinjector |
| Volume | 1 ml |
| Drug Class | Anti-IgE Monoclonal Antibody |
| Therapeutic Category | Antiallergic / Immunologic |
| Manufacturer | Genentech / Roche |
| Prescription Status | Prescription Medicine |
The current product information lists Xolair 150mg/ml as a prefilled syringe and autoinjector presentation for subcutaneous use.
How To Use
Xolair should be administered exactly as prescribed by a qualified healthcare professional. It is given by subcutaneous injection, and the appropriate dose and frequency depend on the condition being treated. For asthma, chronic rhinosinusitis with nasal polyps and food allergy, dosing requires assessment of IgE and other clinical factors; for chronic spontaneous urticaria, dosing is not based on IgE or body weight.
Xolair may be given every 2 or 4 weeks, depending on the prescribed regimen. Do not change the dose or injection schedule without medical advice. Patients who are approved for self-administration should first receive proper training from their healthcare provider.
Xolair is not intended to treat an acute asthma attack or sudden breathing emergency. Continue other prescribed asthma, allergy or related medicines unless your healthcare provider tells you otherwise.
Why Choose Xolair?
Xolair is an established anti-IgE biologic therapy that directly targets an important pathway involved in allergic inflammation. Its targeted mechanism makes it a treatment option for appropriately selected patients with certain allergic diseases who meet the relevant clinical criteria.
